Clinical Trials Logo

Burn clinical trials

View clinical trials related to Burn.

Filter by:

NCT ID: NCT01983280 Completed - Burn Clinical Trials

The Effect of Healing Touch on Sleep Patterns of Pediatric Burn Patients

Sleep5
Start date: October 2009
Phase: N/A
Study type: Interventional

Adequate sleep is an important aspect of any healing process, and because it is known that children recovering from burns suffer long term sleep disruptions, the investigators believe that Healing Touch may improve the quality and quantity of sleep in the pediatric burn population.

NCT ID: NCT01965340 Completed - Burn Clinical Trials

Impact of Therapeutic Drug Monitoring on Anti-Infective Agents Amongst Severely Burned Patients Requiring ICU Admission

Start date: October 2013
Phase: N/A
Study type: Interventional

Sepsis is the major cause of morbidity and mortality amongst burn patients. Burn shock and respiratory failure that used to be the major cause of mortality have progressively been replaced by sepsis and multiple organ failure. It is not rare that treatment failures occurs several weeks, or even months after injury as a consequence of sepsis usually caused by multi-drug resistant (MDR) microorganisms. Introduction of early surgery combined with topical and systemic antibiotherapy dramatically enhanced survival from sepsis after burn trauma, but further improvement is impaired by the rapid development of hard-to-treat MDR bacteria. Correct prescription of anti-infective agents could be one way to curb the steadily increasing development of multidrug resistance. Administration of antibiotic to burn patient is complex: they frequently suffer from kidney dysfunction, they usually experience tremendous shifts of liquids between intra-vascular - inter-cellular and intra-cellular compartments, they often are hypo-albumin and protein-emic, and finally they present with a profoundly modified metabolism. All those aspects make this particular population of patients at high risk of both under or over prescription. Monitoring of drug concentrations in the plasma of patients, so-called TDM for Therapeutic Drug Monitoring, has been introduced to clinical practice for several decades primarily to avoid toxicity of a small number of drugs with narrow therapeutic windows. However, with the increasing availability of detection techniques, the number of drugs that can be measured in the plasma of patients has grown tremendously over the last decade. As a consequence, it is currently possible to monitor drug concentrations not only to prevent toxicity, but also to improve efficacy. For instance, several studies demonstrated that TDM improved antibiotic prescription in different populations of hospitalized patients, including critically ill patients, with a direct impact on outcome. Such studies amongst burn patients are however lacking, although this particular population is at high risk to suffer from mis-prescription. We thus hypothesize that systematic TDM could improve antibiotic prescription in this peculiar population. To this end, we propose to implement a 3-year prospective, randomized, mono-centric, clinical trial that will analyze the impact of systematic TDM on anti-infective agent prescription amongst burned patients.

NCT ID: NCT01957449 Terminated - Burn Clinical Trials

Propranolol in Severely Burned Children

Start date: December 2013
Phase: Phase 2/Phase 3
Study type: Interventional

To determine the safety and efficacy of administration of propranolol for reducing heart rate and blood pressure in burn injury.

NCT ID: NCT01939613 Completed - Burn Clinical Trials

Colloid Improves Organs Function in Resuscitation of Extensive Burn Patients

Start date: July 2010
Phase: N/A
Study type: Observational [Patient Registry]

The present study was to evaluate the effectiveness of colloid compared with crystalloids for fluid resuscitation in critical burn patients with total burn surface area ≥50%.

NCT ID: NCT01926392 Completed - Burn Clinical Trials

Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns

Start date: April 2011
Phase: Phase 4
Study type: Interventional

Partial thickness burns are a common, painful injury requiring a great deal of resources in their care. Silver sulfadizine is a commonly-used topical antimicrobial, but is difficult to remove due to its lipid base. We are comparing a water-based topical antimicrobial therapy to silver sulfadiazine and hypothesize that the water-based therapy is superior in terms of pain control and resources required to deliver care.

NCT ID: NCT01902810 Terminated - Burn Clinical Trials

Protective Effects of Propranolol in Adults

Start date: July 2013
Phase: Phase 2/Phase 3
Study type: Interventional

This efficacy and safety trial will examine the effects and safety of propranolol administered to adult patients with severe burn injury. The investigators hypothesize that propranolol will provide significant benefit to adults following severe burn injury at doses that are safe and do not increase risk of adverse infectious and non-infectious outcomes.

NCT ID: NCT01889537 Completed - Burn Clinical Trials

Low Dose Ketamine VR Analgesia During Burn Care Procedure

VRK
Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of the research is to see whether a low dose of ketamine, a medication used to reduce pain, enhances the effectiveness of a virtual reality video game, which is used as a form of distraction from pain during a painful burn care procedure.

NCT ID: NCT01749371 Completed - Burn Clinical Trials

Vitamin E Supplementation in Burned Patients

Start date: February 2013
Phase: Phase 2/Phase 3
Study type: Interventional

A dietary antioxidant, alpha-tocopherol, will be used to potentially attenuate Vitamin E short- and long-term losses in plasma and adipose, reverse the oxidative stress of burn injury and, in the process, decrease the secondary consequences of burn injury, including lung injury and impaired wound healing. This may improve the quality of life of the burn patient by preventing pathophysiology that may result from oxidative stress and may reduce hospital stay. Our research will lay the foundation for the future development of effective, safe, and economic therapeutic interventions to treat burn injury-associated metabolic abnormalities. Also, it will provide the basis for the development of supplemental regulations and pharmacotherapy to treat burn patients with vitamin E. The risks are very reasonable in relation to the anticipated benefits to our subjects because a) vitamin E is a simple vitamin that is abundant and approved for clinical use, and b) the subjects will be monitored consistently for the minimal increased tendency to bleed.

NCT ID: NCT01562119 Active, not recruiting - Burn Clinical Trials

Long Term Evaluation of Human Acellular Dermal Matrix Allograft For Coverage of the Wound After Extensive Deep Burn

ADM
Start date: January 2011
Phase: N/A
Study type: Observational

The present study was to retrospectively evaluate the long-term outcomes of the cograft acellular dermal matrix (ADM) with autologous thin split-thickness skin for coverage of functional regional wounds in burned patients.

NCT ID: NCT01302457 Withdrawn - Burn Clinical Trials

Oral Care Study on Burn Patients

Start date: September 2007
Phase: N/A
Study type: Observational

There have been multiple articles done regarding oral hygiene on patients in burn and intensive care patients. All articles agree the need for good oral hygiene in these special needs patients. They also note that more research needs to be done on this subject, yet have no direction of how to proceed in this research. Currently, no research has been done on the burn/intensive care patient to see if there is a difference form the non-hospitalized patient which oral hygiene protocol is based on.